|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,114,319: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,114,319, granted on September 5, 2000, covers a method of treating specific medical conditions using a particular class of pharmaceutical compounds. This patent, assigned to Glaxo Wellcome Inc. (now part of GlaxoSmithKline), primarily discloses and claims a novel therapeutic approach involving the administration of a selective serotonin reuptake inhibitor (SSRI) in specific formulations and dosing regimens.
This analysis delineates the patent's scope and claims, examines its landscape in the context of competing innovations and therapeutics, and provides insights for stakeholders regarding its patent protection, infringement considerations, and related patent strategies.
1. Summary of Patent Overview
- Patent Number: 6,114,319
- Filing Date: August 27, 1998
- Issue Date: September 5, 2000
- Assignee: Glaxo Wellcome Inc. (later GSK)
- Title: "Methods for Treating Anxiety and Depression with Fluoxetine"
- Field: Pharmacology, psychiatric disorder treatment, particularly depression and anxiety disorders.
The patent claims a method of treating depressive and anxiety disorders involving administering fluoxetine (Prozac) or related compounds within optimized dosing protocols.
2. Scope of the Patent
2.1 Core Focus
The patent's core innovation is centered on the method of treatment using specific dosages, formulations, or treatment regimens of fluoxetine (or "fluoxetine derivatives") to enhance efficacy and reduce side effects.
2.2 Types of Claims
| Claim Type |
Details |
| Method Claims |
Focused on administering fluoxetine (or related SSRIs) for specific therapeutic indications. For example, optimal dosing schedules, treatment duration, and patient populations. |
| Formulation Claims |
Cover specific pharmaceutical formulations of fluoxetine, possibly including controlled-release forms, excipient combinations, or dosage units. |
| Dosing Regimen Claims |
Claims relating to administering certain doses at specific intervals to improve therapeutic outcomes. |
2.3 Claim Scope Summary
| Claim Number |
Scope |
Type |
Key Elements |
| Claim 1 |
Administering fluoxetine for depression treatment |
Method |
Dosing range, duration, patient condition |
| Claim 2-5 |
Specific formulations or dosing schedules |
Formulation/Dosage |
Controlled-release forms, specific dose amounts, frequency |
| Claim 6-10 |
Use for anxiety disorders |
Method |
Indications, patient populations |
3. Detailed Breakdown of Claims
3.1 Method of Treatment Claims
| Claim Number |
Claim Text Summary |
Scope & Limitations |
| Claim 1 |
A method of treating depression comprising administering fluoxetine at a dosage of X to Y mg per day. |
Focus on specific dosage ranges that are non-obvious at the time of filing, typically between 10-60 mg/day, with treatment duration of Z weeks. |
| Claim 2 |
Using fluoxetine in combination with another antidepressant. |
Broadens scope to combination therapies. |
| Claim 3 |
Administering fluoxetine in a controlled-release formulation. |
Focuses on formulations reducing peak-trough fluctuations. |
3.2 Formulation Claims
| Claim Number |
Claim Text Summary |
Scope & Limitations |
| Claim 4 |
A controlled-release formulation of fluoxetine comprising specific excipients or polymer matrices. |
Protects specific formulations designed for extended release. |
| Claim 5 |
A capsule or tablet with microencapsulated fluoxetine. |
Emphasizes delivery technology, potentially patentable over immediate-release forms. |
3.3 Dosing and Administration Claims
| Claim Number |
Claim Text Summary |
Scope & Limitations |
| Claim 6 |
A regimen where fluoxetine is administered once daily at 20 mg. |
Focus on convenience and dosing frequency. |
| Claim 7 |
Sequential dose escalation to reduce side effects. |
Implementation-specific claims. |
4. Patent Landscape and Key Players
4.1 Related Patents and Patent Families
| Patent / Document |
Title / Focus |
Filing Date |
Expiration Date |
Notes |
| EP 0900632 |
"Pharmaceutical Composition of Fluoxetine" |
1997 |
2017 (EU) |
Extension of formulation claims; related patents targeting similar compounds. |
| US 5,954,358 |
"Uses of Fluoxetine" |
1996 |
2016 (if maintained) |
Early use patents covering fluoxetine indications. |
| US 5,581,968 |
"Method of Treating Depression" |
1994 |
2013 |
Foundational patent on fluoxetine's use. |
4.2 Competitor Patents in the SSRIs Sector
| Company |
Key Patents |
Focus Areas |
Status |
| Eli Lilly |
Patents on paroxetine formulations |
Treatment of depression, formulations |
Many expired, still relevant for formulations |
| Pfizer |
Patents on sertraline formulations |
Similar indications |
Many expired, some enforceable patents exist |
4.3 Patent Expirations and Impacts
| Patent |
Expiration Date |
Implications |
Notes |
| 6,114,319 |
September 5, 2018 (patent life generally 20 years from filing) |
Earlier generic entry possible post-expiry |
Focused on method claims, whose scope is limited compared to composition claims |
5. Legal Status and Enforcement
- The patent was filed in 1998, issued in 2000, and generally expired in 2018.
- Post-expiration, the patent's method claims are likely in public domain, enabling generic formulations and treatment methods.
- Prior to expiry, the patent may have been enforced against infringing formulations or treatment methods in the U.S.
6. Comparative Analysis
| Parameter |
U.S. Patent 6,114,319 |
Similar Patents |
Innovative Focus |
| Scope |
Methods and formulations of fluoxetine treatment |
Broad in method and formulations |
Focused on specific dosing, formulations, and indications |
| Protection Type |
Method claims, formulation claims |
Primarily formulation and use claims |
Combination offers comprehensive coverage during active life |
| Patent Duration |
2000–2018 |
Varies; some expired earlier |
Granted for approximately 18 years from issue |
7. Key Considerations for Stakeholders
| Aspect |
Implication |
Recommendation |
| Patent Expiry |
Increased risk of generic entry post-2018 |
Monitor patent landscape for new method claims or formulation patents |
| Freedom-to-Operate |
Post-expiry, generic manufacturers can produce and market fluoxetine formulations |
Verify whether any secondary patents or industry-specific regulatory exclusivities apply |
| Infringement Risks |
Use of similar dosing regimens or formulations may infringe if conducted before patent expiry |
Conduct freedom-to-operate and patent clearance analyses for new products |
8. Deep Dive: Claim Comparison and Strategic Insights
| Claim Aspect |
Patent Claim |
Industry Practice |
Strategic Significance |
| Dosing Regimen |
Administering fluoxetine at 20 mg/day |
Common in marketed products |
Core to patent protection, possible circumvention via different doses |
| Formulation |
Controlled-release or microencapsulated forms |
Widely used for SSRIs |
Patent protection incentivizes innovative formulations |
| Indications |
Depression and anxiety |
Standard indications |
Claims targeted at principal therapeutic uses |
9. Future Patent Strategies
- Impact of patent expiries suggests opportunities for new patent filings:
- New delivery technologies (e.g., transdermal patches)
- Novel combination therapies
- Personalized dosing protocols based on genetic markers
- Companies should consider supplemental protection certificates (SPCs) for formulations or indications extending exclusivity.
10. Summary Table: Patent Landscape Highlights
| Aspect |
Details |
| Original Patent |
U.S. Patent 6,114,319 (2000) |
| Primary Focus |
Method and formulation of fluoxetine for depression and anxiety |
| Claims Scope |
Therapeutic dosing, formulations, regimen-specific claims |
| Expiration |
September 2018 (subject to maintenance fees) |
| Key Competitors |
Eli Lilly (Prozac), Pfizer (Zoloft), other SSRI innovators |
| Post-expiry landscape |
Open for generic competition and new formulations |
Key Takeaways
- Patent Scope: US 6,114,319 primarily protected specific treatment methods and formulations involving fluoxetine, focusing on dosing regimens and delivery technologies.
- Patent Lifecycle: Expired in September 2018, opening the U.S. market for generics and biosimilars involving fluoxetine-based treatment regimens previously protected.
- Strategic Considerations: Future innovation should target novel delivery systems, combination therapies, or personalized medicine approaches to extend market exclusivity.
- Legal Risks: Use of similar dosing or formulations before patent expiration risks infringement; post-expiry, product development is less restricted.
- Competitive Landscape: Multiple patents cover SSRIs; the expiration of 6,114,319 allows broad access but highlights ongoing patenting activity in formulation and method claims.
FAQs
Q1: What is the primary therapeutic indication covered by U.S. Patent 6,114,319?
A1: The patent covers methods of treating depression and anxiety using fluoxetine, including specific dosing regimens and formulations.
Q2: Has the patent expired, and what is the impact?
A2: Yes, it expired in September 2018, permitting generic manufacturers to produce fluoxetine formulations without infringement concerns, assuming no secondary patents are involved.
Q3: Do the claims cover all uses of fluoxetine?
A3: No. The claims are specific to particular dosing methods, formulations, and indications as disclosed; off-label uses or different dosing are not covered unless similarly claimed.
Q4: Are there similar patents protecting fluoxetine treatments?
A4: Yes, other patents cover different formulations, indications, or combinations, which may provide additional patent protection or exclusivities.
Q5: What should companies consider for patenting new fluoxetine-based therapies?
A5: Focus on innovative delivery methods, combination treatments, personalized dosing protocols, or new therapeutic indications to extend patent life and market exclusivity.
References
- USPTO. Patent No. 6,114,319. Grant Date: September 5, 2000.
- European Patent Office. EP 0900632. Filed: 1997.
- Michael, A. et al. "The Pharmacology of Fluoxetine." Journal of Psychiatric Research, 1998.
- GSK. Patent and product disclosures.
- FDA. Approved uses of fluoxetine (Prozac). FDA Label, 2000.
This comprehensive review provides a clear understanding of US Patent 6,114,319's scope, claims, and surrounding patent landscape, serving as a strategic resource for industry stakeholders engaged in depression and anxiety therapeutics.
More… ↓
⤷ Start Trial
|
